Arcutis Biotherapeutics Inc (NASDAQ: ARQT) kicked off on Friday, down -8.85% from the previous trading day, before settling in for the closing price of $16.16. Over the past 52 weeks, ARQT has traded in a range of $6.99-$17.75.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 349.37% over the last five years. While this was happening, its average annual earnings per share was recorded 50.04%. With a float of $104.41 million, this company’s outstanding shares have now reached $117.85 million.
The firm has a total of 342 workers. Let’s measure their productivity. In terms of profitability, gross margin is 90.27%, operating margin of -65.33%, and the pretax margin is -70.92%.
Arcutis Biotherapeutics Inc (ARQT) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Arcutis Biotherapeutics Inc is 12.01%, while institutional ownership is 102.29%. The most recent insider transaction that took place on Apr 01 ’25, was worth 151,236. In this transaction Director of this company sold 10,000 shares at a rate of $15.12, taking the stock ownership to the 121,944 shares. Before that another transaction happened on Apr 02 ’25, when Company’s Chief Financial Officer sold 9,600 for $15.80, making the entire transaction worth $151,698. This insider now owns 182,774 shares in total.
Arcutis Biotherapeutics Inc (ARQT) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 50.04% per share during the next fiscal year.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Trading Performance Indicators
Take a look at Arcutis Biotherapeutics Inc’s (ARQT) current performance indicators. Last quarter, stock had a quick ratio of 3.97. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.89.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.16, a number that is poised to hit -0.21 in the next quarter and is forecasted to reach 0.30 in one year’s time.
Technical Analysis of Arcutis Biotherapeutics Inc (ARQT)
Analysing the last 5-days average volume posted by the [Arcutis Biotherapeutics Inc, ARQT], we can find that recorded value of 2.96 million was better than the volume posted last year of 2.38 million. As of the previous 9 days, the stock’s Stochastic %D was 42.97%. Additionally, its Average True Range was 1.27.
During the past 100 days, Arcutis Biotherapeutics Inc’s (ARQT) raw stochastic average was set at 65.88%, which indicates a significant increase from 13.47% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 69.90% in the past 14 days, which was lower than the 77.03% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.23, while its 200-day Moving Average is $11.56. Now, the first resistance to watch is $15.76. This is followed by the second major resistance level at $16.79. The third major resistance level sits at $17.54. If the price goes on to break the first support level at $13.98, it is likely to go to the next support level at $13.23. Should the price break the second support level, the third support level stands at $12.20.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Key Stats
The company with the Market Capitalisation of 1.75 billion has total of 118,638K Shares Outstanding. Its annual sales at the moment are 196,540 K in contrast with the sum of -140,040 K annual income. Company’s last quarter sales were recorded 71,360 K and last quarter income was -10,790 K.
